Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures-Reference-Cited by-同舟云学术

Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures

Published:2021-04-02 Issue: Volume: Page:1-8
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Son Kyung-Bok¹^ORCID

Affiliation:

1. Pharmaceutical Economics and Policy, School of Pharmacy, Sungkyunkwan University, Suwon-si, Republic of Korea

Funder

National Research Foundation funded by the Ministry of Education

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2021.1908890

Reference41 articles.

1. The diffusion of generics after patent expiry in Germany

2. Competition in off-patent drug markets: Issues, regulation and evidence

3. Generic Drugs in the United States: Policies to Address Pricing and Competition

4. Guo JJ, Kelton CM. Competition between brand-name and generic drugs. Handbook of pharmaceutical public policy. New York: Haworth Press, Inc; 2007. p. 395–416.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Which factor reduces pharmaceutical expenditure, number of entrants or price variance? Updated generic drug markets in South Korea;Health Economics Review;2024-08-14

2. A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China;Frontiers in Pharmacology;2023-09-05

3. Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?;Frontiers in Public Health;2023-08-03

4. Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?;Frontiers in Public Health;2022-09-14

5. The impacts of the “4+7” pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study;Frontiers in Pharmacology;2022-08-17